2014
2016
The
FASTEST
GROWING
2014 - 2016:
300%
increase in the
number of hospitals
using Aggrastat HDB
GP IIb/IIIa inhibitor
among interventional
cardiologists in the U.S.
$90,000
The average amount a 100-bed acute care hospital will
save per year in acquisition costs by making the transition.*
Used in over
Over
90,000
1,200
patients
hospitals are
currently using
since HDB
approval (2013)
Aggrastat HDB
Hospitals are continuing to make Aggrastat HDB their primary GPI based on:
Established
Clinical
Data
ACC/AHA/SCAI
Class I
Recommended1, 2
Safety
Profile
No significant
difference in
bleeding when
compared to
standard of care
Acquisition
Savings
50-70%
acquisition
savings compared
to other branded
and generic GPIs
49
More than
peer-reviewed
publications on Aggrastat HDB
IMPORTANT SAFETY INFORMATION
HIGH-DOSE BOLUS (HDB) REGIMEN: Administer intravenously 25 mcg/kg within
5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine
clearance ≤60 mL/min, give 25 mcg/kg within 5 minutes and then 0.075 mcg/kg/min.
Indication: Aggrastat is indicated to reduce the rate of thrombotic cardiovascular
events (combined endpoint of death, myocardial infarction, or refractory ischemia/
repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome
(NSTE-ACS).
CONTRAINDICATIONS: Known hypersensitivity to any component of Aggrastat;
history of thrombocytopenia with prior exposure to Aggrastat; active internal
bleeding, or history of bleeding diathesis, major surgical procedure or severe physical
trauma within the previous month.
PA-TP-03
WARNINGS AND PRECAUTIONS: Aggrastat can cause serious bleeding. If bleeding
cannot be controlled discontinue Aggrastat; thrombocytopenia: discontinue Aggrastat
and heparin.
ADVERSE REACTIONS: Bleeding is the most commonly reported adverse reaction.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit MedWatch or call 1-800-FDA-1088.
* Medicure Data on file.
1. Levine GN et al. J Am Coll Cardiol 2011;58:e44-e122
2. Amsterdam EA et al. J Am Coll Cardiol 2014;64:2645-2687
Please see Brief Summary on reverse.
Contact a Product Specialist:
1-800-509-0544 (#5) or visit www.aggrastatHDB.com